Deubiquitinase JOSD2 alleviates colitis by inhibiting inflammation via deubiquitination of IMPDH2 in macrophages
Authors:
Open Access
- 17 December 2024
- journal article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (2) , 1039-1055
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatmentActa Pharmaceutica Sinica B, 2024
- Cancer in Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2022
- USP25 Deficiency Exacerbates Acute Pancreatitis via Up-Regulating TBK1–NF-κB Signaling in MacrophagesCellular and Molecular Gastroenterology and Hepatology, 2022
- Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradationCell Biology International, 2022
- Ubiquitin-specific protease 47 regulates intestinal inflammation through deubiquitination of TRAF6 in epithelial cellsScience China Life Sciences, 2022
- A20 functions as a negative regulator in macrophage for DSS-induced colitisInternational Immunopharmacology, 2021
- Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progressionActa Pharmaceutica Sinica B, 2021
- Most Tissue-Resident Macrophages Except Microglia Are Derived from Fetal Hematopoietic Stem CellsImmunity, 2015
- Macrophage-Restricted Interleukin-10 Receptor Deficiency, but Not IL-10 Deficiency, Causes Severe Spontaneous ColitisImmunity, 2014
- Ly6Chi Monocytes in the Inflamed Colon Give Rise to Proinflammatory Effector Cells and Migratory Antigen-Presenting CellsImmunity, 2012